Inspire in 2007 was granted a license to InSite’s patents, as well as a sublicense to Pfizer’s patents. InSite and Pfizer each have primary responsibility for enforcing rights of their respective ...
InSite Vision And Inspire Pharmaceuticals In $32 Million Licensing Deal On AzaSite DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. announced today the signing of an exclusive licensing agreement with ...
Totally didn’t see this one coming. As I noted in my last baleful blog on the abandonment of AzaSite, I had forsaken all hope of ever being able to prescribe it without creating myriad hardships for ...
Please provide your email address to receive an email when new articles are posted on . Has there ever a better medicine that had a rougher go than AzaSite? Seriously. AzaSite is the floppy eyelid ...
Inspire Pharmaceuticals Announces FDA Approval Of AzaSite(TM) DURHAM, N.C. -- Inspire Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved AzaSite(TM) ...
InSite Vision Completes DOUBle Phase 3 Clinical Study of AzaSite Plus™ and DexaSite™ for the Treatme
ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) today announced that the last patient has completed dosing and evaluation in the DOUBle Phase 3 clinical trial of AzaSite ...
InSite Vision Announces Court Judgment Upholding All AzaSite® Patents in Patent Infringement Lawsuit
InSite Vision Announces Court Judgment Upholding All AzaSite ® Patents in Patent Infringement Lawsuit Against Sandoz Inc. ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) ...
InSite Vision Inc. initiated patient enrollment in two Phase III trials of its lead drug, AzaSite, to treat bacterial conjunctivitis, commonly known as "pink eye." The company received FDA approval ...
InSite Vision (INSV) announced that Merck (MRK), through its subsidiary Inspire Pharmaceuticals, has agreed to amend the payment terms of the existing AzaSite 1% license agreement. On a quarterly ...
ALAMEDA, Calif.--(BUSINESS WIRE)--Sept. 29, 2005--InSite Vision Incorporated (AMEX:ISV) -- an ophthalmic therapeutics, diagnostics and drug-delivery company -- today announced the completion of ...
MONTREAL, QUEBEC--(Marketwired - Jul 24, 2015) - Knight Therapeutics Inc. (GUD.TO) ("Knight") a leading Canadian specialty pharmaceutical company, today announced the signing of an exclusive agreement ...
Co announces the FDA has approved ISV's New Drug Application for AzaSite for the treatment of bacterial conjunctivitis. AzaSite is formulated with DuraSite, ISV's patented drug delivery vehicle which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results